AWA
ABBV icon

Acumen Wealth Advisors’s AbbVie ABBV Stock Holding History

Acumen Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44M Buy
9,708
+5,487
+130% +$1.18M 0.52% 48
2026
Q1 		$918K Buy
4,221
+3,081
+270% +$683K 0.25% 67
2025
Q4 		$260K Buy
+1,140
New +$260K 0.08% 64

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Acumen Wealth Advisors's ABBV Position: Q2 2026 in Review

Acumen Wealth Advisors increased its AbbVie (ABBV) stake by 130% in Q2 2026, buying an estimated $1.18M and bringing the position to 9,708 shares worth $2.44M. The position accounts for 0.52% of the portfolio, ranked #48.

Acumen Wealth Advisors first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Acumen Wealth Advisors held 9,708 shares of AbbVie worth $2.44M as of Q2 2026.
  • Acumen Wealth Advisors bought 5,487 AbbVie shares in Q2 2026, an estimated $1.18M.
  • AbbVie made up 0.52% of Acumen Wealth Advisors's portfolio in Q2 2026, its #48 holding.
  • Acumen Wealth Advisors first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Acumen Wealth Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.